742 related articles for article (PubMed ID: 17427044)
1. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
2. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
3. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
Rektorova I; Balaz M; Svatova J; Zarubova K; Honig I; Dostal V; Sedlackova S; Nestrasil I; Mastik J; Bares M; Veliskova J; Dusek L
Clin Neuropharmacol; 2008; 31(5):261-6. PubMed ID: 18836343
[TBL] [Abstract][Full Text] [Related]
4. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
10. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
11. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
15. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
Barone P; Lamb J; Ellis A; Clarke Z
Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
[TBL] [Abstract][Full Text] [Related]
16. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Hersh BP; Earl NL; Hauser RA; Stacy M
Mov Disord; 2010 May; 25(7):927-31. PubMed ID: 20461810
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
19. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.
Badarny S; Stern A; Susel Z; Honigman S; Hocherman S
Acta Neurol Scand; 2006 May; 113(5):294-300. PubMed ID: 16629764
[TBL] [Abstract][Full Text] [Related]
20. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
